Altimmune financials
$2.97+0.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $26.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $37.0K | $362.0K |
| Gross profit | $0.00 | $0.00 | $26.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $37.0K | $362.0K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$26.2M | -$24.2M | -$28.9M | -$20.9M | -$22.9M | -$21.8M | -$24.9M | -$24.8M | -$26.7M | -$26.8M | -$33.6M | -$22.5M |
| Net income | -$22.8M | -$22.9M | -$27.4M | -$19.0M | -$22.1M | -$19.6M | -$23.2M | -$22.8M | -$24.6M | -$24.4M | -$31.6M | -$20.7M |
| Net margin | — | — | −105223.1% | −380280.0% | −442920.0% | −392100.0% | −463600.0% | −456900.0% | −492800.0% | −487880.0% | −85516.2% | −5710.2% |
| Diluted EPS | $-0.12 | $-0.18 | $-0.26 | $-0.21 | $-0.27 | $-0.26 | $-0.33 | $-0.32 | $-0.35 | $-0.34 | $-0.54 | $-0.39 |
| EBITDA | -$26.2M | -$24.2M | -$28.9M | -$20.8M | -$22.9M | -$21.8M | -$24.8M | -$24.7M | -$26.7M | -$26.7M | -$21.1M | -$22.4M |
| Operating cash flow | -$24.2M | -$20.9M | -$19.4M | -$11.9M | -$19.4M | -$16.8M | -$18.3M | -$27.1M | -$18.1M | -$16.4M | -$16.5M | -$20.5M |
| Free cash flow | -$24.3M | -$21.0M | -$19.4M | -$11.9M | -$19.4M | -$16.8M | -$18.3M | -$27.1M | -$18.1M | -$16.4M | -$16.5M | -$20.5M |
| Diluted shares | 185.4M | 124.5M | 106.0M | 89.4M | 81.5M | 75.5M | 71.2M | 71.1M | 70.9M | 70.8M | 58.5M | 53.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.0M | $97.6M | $43.8M | $61.2M | $183.1M | $49.1M |
| Short-term investments | $263.3M | $233.9M | $229.7M | $149.5M | $0.00 | $100.7M |
| Total debt | $34.7M | $34.5M | $34.3M | $14.4M | $14.3M | $0.00 |
| Total assets | $527.2M | $335.6M | $279.9M | $218.4M | $190.3M | $157.3M |
| Total liabilities | $53.0M | $51.6M | $55.0M | $32.8M | $29.0M | $15.1M |
| Shareholders' equity | $474.2M | $284.0M | $224.9M | $185.6M | $161.4M | $142.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology